Larimar Therapeutics, Inc.
LRMR
$0.03
Change (1 day)
$13.68
Year High
$3.01
Year Low
Categories
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
P/B ratio for Larimar Therapeutics, Inc. (LRMR)
P/B ratio as of 2023: 2.44
According to Larimar Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.44. At the end of 2022 the company had a P/B ratio of 0.96.
P/B ratio history for Larimar Therapeutics, Inc. from 2011 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.44 |
| 2022 | 0.96 |
| 2021 | 2.88 |
| 2020 | 2.84 |
| 2019 | -176.84 |
| 2018 | 1.71 |
| 2017 | 1.62 |
| 2016 | 0.71 |
| 2015 | 1.00 |
| 2014 | 8.56 |
| 2013 | 14.65 |
| 2012 | 64.07 |
| 2011 | 0.00 |